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The ethyl 2-(6-substituted benzo[d]thiazol-2-ylamino)-2-oxoacetate derivatives (OX 1e9) were prepared
using a one-step reaction. The in vitro inhibitory activity of the compounds against protein tyrosine
phosphatase 1B (PTP-1B) was evaluated. Compounds OX-(1, 6 and 7) were rapid reversible (mixed-type)
inhibitors of PTP-1B with IC50 values in the low micro-molar range. The most active compounds OX-(1, 6
and 7) were docked into the crystal structure of PTP-1B. Docking results indicate potential hydrogen
bond interactions between the oxamate group in all compounds and the catalytic amino acid residues
Arg221 and Ser216. The compounds were evaluated for their in vivo hypoglycemic activity, showing
significant lowering of plasma glucose concentration in acute normoglycemic model and oral glucose
tolerance test similarly at the effect exerted for hypoglycemic drug glibenclamide.
 2012 Elsevier Masson SAS. All rights reserved.1. Introduction
Diabetes mellitus is a chronic and progressive disease of meta-
bolic deregulation characterized by insulin resistance in peripheral
tissues (liver, muscle, and adipose), and impaired insulin secretion
by the pancreas [1].
Type-2 diabetes and obesity are related with the deficiency in
insulin receptor signaling and is supposed to be recovered by the
inhibition of a certain protein-tyrosine phosphatases involved in
the down-regulation of insulin receptor, which causes prolonged
phosphorylation of the insulin receptor kinase [2e4]. The protein-
tyrosine phosphatase 1B (PTP-1B) plays a key role in cellular
signaling and in several human diseases, particularly diabetes and
obesity [5]. This enzyme is a novel attractive therapeutic target for
the treatment of diabetes [6]. Recently, our group reported a series
of 2-arylsulfonylaminobenzothiazoles, which were weak inhibitors
of PTP-1B (Fig. 1) [7].mírez-Martínez.
.
avarrete-Vazquez).
son SAS. All rights reserved.
rete-Vazquez, et al., Synthes
-tyrosine phosphatase 1B inhHowever, compounds displayed appreciable in vivo activity in
a non-insulin-dependent diabetes mellitus murine model,
comparable to glibenclamide [7]. In order to find new class of
compounds with hypoglycemic action, we report in this article the
one-step synthesis of ethyl 2-(6-substituted benzo[d]thiazol-2-
ylamino)-2-oxoacetate derivatives (OX-(1e9), Table 1), their
in vitro inhibitory activity on the PTP-1B, molecular docking of the
most active compounds as well as the in vivo hypoglycemic effect in
normoglycemic rats.
2. Results and discussion
2.1. Chemistry
Compounds OX-1 to OX-8 were synthesized starting from 2-
amino-6-substituted benzo[d]thiazole (10e17), via a coupling
reaction with ethyl chlorooxoacetate (18), in the presence of trie-
thylamine. Compound OX-9 was prepared by catalytic reduction of
compound OX-8. Title compounds were recovered with 44e98%
yields (Table 1). Compounds were purified by recrystalization or
by column chromatography. The chemical structures of the
synthesized compounds were confirmed on the basis of their
spectral data (NMR and mass spectra), and their purity ascertainedis, in vitro and in silico screening of ethyl 2-(6-substituted benzo[d]
ibitors, European Journal of Medicinal Chemistry (2012), doi:10.1016/
Fig. 1. Structure of 2-arylsulfonylaminobenzothiazoles inhibitors of PTP-1B [7].
Fig. 2. Inhibition of PTP-1B activity by OX-(1e9) compounds. Inhibition assays were
performed at 37 C and pH 7.0 at a fixed substrate final concentration (2.5 mM p-NPP),
which is a value close to that of Km for PTP-1B at pH 7.0. The final concentration of each
compound in the reaction assay was 40 mM. Each assay (final volume 1 ml) was started
with 0.16 mg of PTP-1B. Control experiment was carried out using DMSO. Each datum
represents the means  S.E.M. of four distinct assays. Residual activity, expressed as
percentage, is defined as the ratio between enzyme activity measured in the presence
G. Navarrete-Vazquez et al. / European Journal of Medicinal Chemistry xxx (2012) 1e102by microanalysis. Physical constants of the title compounds are
shown in Table 1.
In the nuclear magnetic resonance spectra (1H NMR; d ppm), the
signals of the respective protons of the compoundswere verified on
the basis of their chemical shifts, multiplicities, and coupling
constants. The aromatic region of the 1H NMR spectrum contained
an ABX pattern signals ranging from d 7.06e8.24 ppm (dd,
Jm ¼ 1.0e2.4; Jo ¼ 7.5e8.8 Hz), 7.61e7.89 (d, Jo ¼ 8.8 Hz), and
7.59e8.43 (d, Jm ¼ 1.1e2.6 Hz) attributable to H-5, H-4, and H-7, of
the benzothiazole-6-substituted structure, respectively. The signals
for ethyl oxamate were found ranging from d 3.80e4.32 ppm
assignable to CH2, and 1.20e1.34 attributable to CH3.of the inhibitor and that of the control.2.2. In vitro PTP-1B inhibition assay
To test the ability of each compound to inhibit PTP-1B, aliquots
of stock solutions (dissolved in DMSO to prepare 20 mM) were
diluted with the assay buffer, containing 2.5 mM p-nitrophenyl
phosphate (p-NPP), to the final concentration of 40 mM. Samples
were incubated at 37 C, and the reactions were initiated by adding
an appropriate enzyme aliquot. Fig. 2 shows that compounds OX-1,
OX-6, and OX-7 strongly reduce the PTP-1B activity, whereas all
other compounds showed weaker activity.
Taking into account the results of the above preliminary anal-
yses, we performed additional assays on the most active
compounds OX-1, OX-6, and OX-7 to explore the type of inhibition.
Appropriate aliquots of PTP-1B were incubated in the presence of
a 125-fold molar excess of inhibitor for 1 h at two differing
temperature, 4 C and 37 C. Control experiments were performed
adding DMSO instead of the inhibitor solution. After this interval
time, the enzyme solutions were diluted 400-fold with the assay
solution, and the residual enzyme activity was measured. The
results, shown in the Fig. 3, demonstrate that the recovery of the
enzyme activity is almost complete in all cases, suggesting that all
OX-1, OX-6, and OX-7 act as reversible inhibitors.
To assess the ability of OX-1, OX-6, and OX-7 to behave as slow-
binding inhibitors, we studied the PTP-1B catalyzed hydrolysis of p-Table 1
Synthesis and physicochemical data for derivatives OX-(1e9).
Compd R MW Mp (C) Unoptimized yield (%)
OX-1 eCH3 265 163e165 52
OX-2 eH 251 187e188 49
OX-3 eOCH3 280 182e184 45
OX-4 eOCH2CH3 295 176e178 44
OX-5 eSO2CH3 329 209e212 98
OX-6 eCl 285 218e221 47
OX-7 eF 269 214e215 63
OX-8 eNO2 295 255(dec.) 80
OX-9 eNH2 265 282 (dec.) 92
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concentrations, measuring the time-course of p-nitrophenol
release at 400 nm. In all cases we found that initial rates decrease
with increasing inhibitor concentrations, and curves maintain
linear monophasic behaviors as time progresses, indicating that the
rapid equilibrium conditions occur in the formation of
enzymeeinhibitor complexes. Identical behavior was found pre-
incubating PTP-1B with inhibitors for 30 min before the activity
assay. Taken together our results suggest that both association and
dissociation of inhibitors to the enzyme are fast events, excluding
the hypothesis that these compounds are slow-binding inhibitors.
To better evaluate the inhibitory power of these compounds, their
IC50 values were determined. Fig. 4 show the
concentrationeresponse plots by the most active compounds OX-1,
OX-6, and OX-7. Table 2 summarizes the corresponding IC50 values,
which are in the low micro-molar range.
Thus, our assay system is operated under non-tight binding
conditions in the case of each inhibitor examined since IC50 is
greater than 5-fold over enzyme concentration (10 nM in all assays)
and the approximation that [inhibitor] free ¼ [inhibitor] total is
valid.Fig. 3. Inhibition reversibility assay. Aliquots of PTP-1B were incubated in the presence
of 100 mM of each compound for 1 h at 4 C (black bar) or 37 C (white bar). Then the
enzyme was diluted 400-fold with the assay solution to measure the residual activity
(37 C, 5 mM pNPP final concentration). Control experiments were carried out adding
DMSO. All tests were performed in triplicate. The data represent the mean  S.E.M.
is, in vitro and in silico screening of ethyl 2-(6-substituted benzo[d]
ibitors, European Journal of Medicinal Chemistry (2012), doi:10.1016/
Fig. 4. The IC50 values were determined by plotting the relative activity of PTP-1B
versus inhibitor concentration. For each inhibitor, 15e20 different inhibitor concen-
trations were used. All tests were performed in quadruplicate. The data represent the
means  S.E.M.
Table 2
IC50 values for the most active compounds against
PTP-1B.
Compound IC50 (mM)
OX-1 11.0  1.8
OX-6 10.1  0.4
OX-7 8.7  0.3
The data represent the IC50 value  S.E.M.
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measured the rate of PTP-1B-catalyzed hydrolysis of p-nitrophenyl
phosphate at high substrate concentration (10-fold the Km value of
the enzyme) in the presence of increasing concentrations of each
compound. The results obtained for OX-1, OX-6, and OX-7 are
reported in Fig. 5. We can observe that, by increasing the inhibitor
concentration, the hydrolysis rate is reduced near to zero, sug-
gesting that the binding of inhibitor to enzyme produces an inac-
tive EI complex.
To determine the kinetic mechanism of inhibition, we studied
the dependence of enzyme main kinetic parameters (Km and Vmax)
from the inhibitors concentration. For each compound, we
measured the initial hydrolysis rate using height substrate final
concentrations (0.5e40 mM range), in the presence of increasing
concentrations of each compound (Fig. 6). Experimental data was
analyzed by the double reciprocal plot method.
All reciprocal plots for OX-1, OX-6, and OX-7 show straight lines
that intersect each other in the left panel demonstrating that they
are mixed-type inhibitors. This is confirmed by the fact that
increasing inhibitor concentration is accompanied by the increase
of Km values and the decrease of Vmax (values Figs. 6e8).
To determine the Ki and the a values for the mixed-type
inhibitors OX-1, OX-6, and OX-7 we considered the model repre-
sented in Scheme 1.
In this model, the inhibitor binds both the free enzyme, E, and
the enzymeesubstrate complex, ES. The EI has lower affinity for S
than E (a> 1), and ESI is non-productive.We calculated the value of
Ki (mixed-type) by replotting the slope of the straight lines of the
double reciprocal plot versus [I], using the following equation:
slope ¼ Km
Kt  Vmax  ½I þ
Km
Vmax
The results are reported in Table 3.2.3. Molecular docking of compounds OX-(1, 6 and 7) with PTP-1B
In order to gain insight into the putative binding mode of the
most active compounds with PTP-1B, these compounds were
docked with a crystallographic structure of human PTP-1B using
AutoDock4 [11]. The crystallographic structure was obtained from
the Protein Data Bank (PDB), accession code 1C83 [8]. PTP-1B is co-
crystallized with 6-(oxalyl-amino)-1H-indole-5-carboxilic acid
which shows an extensive hydrogen bond networkwith residues in
the catalytic site. The catalytic residues, Arg221 and Asp181, play
a key role in the binding mode of the co-crystallized ligand (Fig. 9).Fig. 5. The residual enzyme activity was measured at 37 C and pH 7.0 using 25 mM
pNPP as substrate. The inhibitors concentrations used were: 2.5, 5.0, 10, 25, 50, 100 and
200 mM. The symbols are: OX-1, C; OX-6, ,; OX-7, :. All tests were performed in
quadruplicate. The data represent the mean  S.E.M.
is, in vitro and in silico screening of ethyl 2-(6-substituted benzo[d]
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Fig. 6. [A] Double reciprocal plot of OX-1 (1/v versus 1/[S]). The concentrations of inhibitor used were: 0 mM, C; 5 mM, B; 10 mM, -; 15 mM, ,. All tests were performed in
quadruplicate. Dependence of main kinetic parameters Km [B] and Vmax [C] from the concentration of compound OX-1. The data represent the Km or Vmax values  S.E.M.
Fig. 7. [A] Compound OX-6: double reciprocal plot (1/v versus 1/[S]). The concentrations of inhibitor used were: 0 mM,C; 3 mM,B; 6 mM, :; 9 mM,7; 12 mM, -. All tests were
performed in quadruplicate. Dependence of main kinetic parameters Km [B] and Vmax [C] from the concentration of compound OX-6. The data represent the Km or Vmax
values  S.E.M.
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thiazol-2-ylamino)-2-oxoacetates as protein-tyrosine phosphatase 1B inhibitors, European Journal of Medicinal Chemistry (2012), doi:10.1016/
j.ejmech.2012.04.025
Fig. 8. [A] Compound OX-7: double reciprocal plot (1/v versus 1/[S]). The concentrations of inhibitor used were: 0 mM,C; 3 mM,B 6 mM, :; 9 mM,7; 12 mM, -. All tests were
performed in quadruplicate. Dependence of main kinetic parameters Km [B] and Vmax [C] from the concentration of compound OX-7. The data represent the Km or Vmax
values  S.E.M.
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crystal ligand and benzothiazole derivatives along with their cor-
responding experimental Ki values. In general, the binding energies
are similar. This result is in line with the comparable experimental
activity of the three compounds. In addition, all compounds
showed better affinities than the crystal ligand.
Fig. 10 shows the binding mode of OX-1. It has a similar binding
as the co-crystal ligand and both form a similar hydrogen bond
network with the catalytic site.
Fig. 11 shows a comparison of the binding mode of the three
most active compounds with 6-(oxalyl-amino)-1H-indole-5-
carboxilic acid. The figures clearly show that the three benzothia-
zole derivatives have the same binding mode. In addition, all three
docked benzothiazole derivatives share the same binding pattern
and pharmacophoric interactions as the co-crystal ligand of PTP-1B
(1C83). It is notable the three-dimensional similarity of the bindingE S
I
+ ES
K
i
E P+
+
EI S+ ESI
I
+
αK
i
K
s
αK
s
k
2
Scheme 1. Linear mixed-type inhibition.
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indole-5-carboxilic acid.
Fig.12 depicts the 2D interactionsmaps of the 6-(oxalyl-amino)-
1H-indole-5-carboxilic acid and OX-1. A three-dimensional
comparison of the binding conformation of the co-crystal ligand
and docked OX-1 is also shown. Hydrogen bond network is
conserved by OX-1 and analogs, with Gly220, Arg221, Asp181,
Ser216. As compared to the crystal ligand, OX-1 and analogs lack of
two important hydrogen bonds with Lys120 and Gln262. These
considerations could be taken into account for designing new
compounds. Interestingly, Asp181, Cys215 and Arg221 are catalytic
residues [9]. According to the models predicted by Autodock4, the
studied benzothiazole derivatives bind into the catalytic site of
PTP-1B.2.4. In vivo hypoglycemic activity
Compounds OX-1 and OX-6 were evaluated for in vivo hypo-
glycemic activity using a normoglycemic rats. Glibenclamide was
taken as positive control [7]. The hypoglycemic activity of bothTable 3
The inhibition constants for compounds OX-1, OX-6, and OX-7.
Compound Ki (mM) a Inhibition type
OX-1 6.2  0.7 4.5 Linear mixed-type
OX-6 7.9  0.6 3.8 Linear mixed-type
OX-7 7.9  0.6 1.8 Linear mixed-type
Data represent Ki values  S.E.M.
is, in vitro and in silico screening of ethyl 2-(6-substituted benzo[d]
ibitors, European Journal of Medicinal Chemistry (2012), doi:10.1016/
Fig. 9. [A] Binding mode of the co-crystal ligand with PTP-1B showing an extensive hydrogen bonds network. Hydrogen bonds are depicted with yellow dashes. [B] Catalytic
binding site of PTB-1B. Surface in red shows the residues (Asp181, Ser216, Gly220 and Arg221) that participate in the hydrogen bond network. (For interpretation of the references
to color in this figure legend, the reader is referred to the web version of this article.)
Table 4
Docking results of the co-crystal ligand and benzothiazole derivatives into the
catalytic site of PTP-1B.
Compound Binding energy
DG (Kcal/mol)
Experimental inhibition
constant Ki (mM)
Co-crystal
ligand
6.01 14.0 [8]
OX-1 6.37 6.2
OX-6 6.35 7.9
OX-7 6.01 7.9
G. Navarrete-Vazquez et al. / European Journal of Medicinal Chemistry xxx (2012) 1e106compounds was determined using a 100 mg/kg single dose.
Compound OX-1 demonstrated significant hypoglycemic activity,
by lowering glycemia ranging from 26% to 37%. The effect was
consistent during the first 5 h of experiment (Fig. 13). Compound
OX-6 showed similar effects than glibenclamide during the first 3 h,
lowering the glycemia until 30%. The most pronounced effect of
both compounds was observed during the first 3e5 h of post-
intragastric administration.
2.5. Oral glucose tolerance test
Compounds OX-1 and OX-6 were tested in glucose-fed normal
rats, and they significantly prevent the rise of blood glucose (more
than 20%) when compared with control of glucose-fed normal rats,
repaglinide and glibenclamide (Fig. 14). Both compounds signifi-
cantly diminish hyperglycemic curve induced by overdose of
glucose (2 g/kg). This effect is similar to that exercised byFig. 10. Binding model of OX-1 in the catalytic site of PTP-1B. Hydrogen bonds are
depicted with yellow dashes. (For interpretation of the references to color in this figure
legend, the reader is referred to the web version of this article.)
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exerts a hypoglycemic effect of equal potency and efficacy that
repaglinide, confirming the hypoglycemic effects observed in the
acute normoglycemic model.3. Conclusion
We report the synthesis of nine ethyl 2-(6-substituted benzo[d]
thiazol-2-ylamino)-2-oxoacetate derivatives which were obtained
with modest yields, and evaluated these compounds for their
protein tyrosine phosphatase 1B inhibitory activity. SeveralFig. 11. [A] Docked benzothiazole derivatives and co-crystal ligand. They represent the
lowest energy conformation estimated by Autodock4. [B] Docked benzothiazole
derivatives into the catalytic binding site. Residues forming hydrogen bonds in red:
Asp181, Ser216, Gly220 and Arg221. Residues making van der Waals contacts in yellow:
Tyr46, Arg47, Val49 and Phe182. (For interpretation of the references to color in this
figure legend, the reader is referred to the web version of this article.)
is, in vitro and in silico screening of ethyl 2-(6-substituted benzo[d]
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Fig. 12. 2D dimensional interaction maps of the crystal ligand and OX-1.
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Fig. 13. Effect of a single dose of OX-1 and OX-6 (100 mg/kg; intragastric, n ¼ 5) in
normoglycemic rats. ISS: Isotonic saline solution. *p < 0.05 versus ISS group.
Fig. 14. Oral glucose tolerance test. Effect of a single dose of OX-1 and OX-6 (100 mg/
kg; intragastric route, n ¼ 5) in normoglycemic rats. ISS: Isotonic saline solution.
*p < 0.05 versus ISS group.
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activity in the low micro-molar range. Compounds OX-1, 6 and 7
exhibited the most promising activity as reversible and non-slow
binding mixed-type inhibitors of PTP-1B. Docking results indicate
potential hydrogen bond interactions between the oxamate group
in all compounds and the catalytic amino acid residues Arg221 and
Ser216. Compounds OX-1, 6 and 7 were two to four-times more
active than previously benzothiazole inhibitors synthesized by our
group [7].
The in vivo hypoglycemic activities of these compounds make
them a suitable leads to develop new chemical entities for potential
use in the treatment of diabetes.4. Experimental
4.1. Chemistry
Melting points were determined on an EZ-Melt MPA120 auto-
mated melting point apparatus from Stanford Research Systems
and are uncorrected. Reactions were monitored by TLC on 0.2 mm
precoated silica gel 60 F254 plates (E. Merck). 1H NMR spectra were
recorded on a Varian Oxford (400 MHz) and 13C NMR (100 MHz)
instrument. Chemical shifts are given in ppm relative to tetrame-
thylsilane (Me4Si, d ¼ 0) in DMSO-d6; J values are given in Hz. The
following abbreviations are used: s, singlet; d, doublet; q, quartet;
dd, doublet of doublet; t, triplet; m, multiplet; bs, broad signal. MS
were recorded on a JEOL JMS-700 spectrometer by Fast Atom
Bombarded [FAB (þ)]. Starting materials were commercially avail-
able from Aldrich and used without purification.
4.1.1. General method of synthesis of ethyl 2-(6-substituted benzo
[d]thiazol-2-ylamino)-2-oxoacetates (1e8)
To a solution of 2-amino-6-substituted benzo[d]thiazole
(0.0015 mol) in dichloromethane was added triethylamine
(1.2 equiv.). The reaction mixture was stirred at 5 C for 15 min.
After that, a solution of ethyl chlorooxoacetate (0.0018 mol,
1.2 equiv.) was added droopingly. The reaction mixture was stirred
at room temperature for 9e32 h. After complete conversion as
indicated by TLC, the solvent was removed in vacuo, the residuewas
neutralized with saturated NaHCO3 solution, and the aqueous layer
was extracted with ethyl acetate (3  15 mL), washed with water
(3  20 mL), and dried over anhydrous Na2SO4. The solvent was
evaporated in vacuo and the precipitated solids were recrystalized
from a mixture of ethanol:acetone or purified by column
chromatography.
4.1.1.1. Ethyl 2-(6-methylbenzo[d]thiazol-2-ylamino)-2-oxoacetate
(OX-1). Yield: 52%, mp: 163e165 C. 1H NMR (400 MHz, DMSO-
d6) d: 7.69 (1H, s, H-7), 7.65 (1H, d, Jo ¼ 8 Hz, H-4), 7.25 (1H, dd,
Jo ¼ 7.5 Hz, Jm ¼ 1 Hz, H-5), 4.29 (2H, q, CH2), 2.38 (3H, s, CH3),
1.2 (3H, t, CH3) ppm; 13C NMR (100 MHz, DMSO-d6) d: 160.2 (C-
20), 158.4 (C-10), 158.1 (C-2), 146.6 (C-3a), 134.9 (C-7a), 132.6 (C-6),
129.0 (C-5), 122.6 (C-7), 121.3 (C-4), 63.9 (CH2), 22.2 (CH3) 15.0
(CH3) ppm; MS/FABþ: m/z 265 (M þ Hþ). HRMS (FABþ): m/z
265.07062 [M þ H]þ (Calculated for C12H12N2O3SHþ 265.0647).
4.1.1.2. Ethyl 2-(benzo[d]thiazol-2-ylamino)-2-oxoacetate (OX-
2). Yield: 49%, mp: 187e188 C. 1H NMR (400 MHz, DMSO-d6) d:
8.03 (1H, d, Jo ¼ 7.88 Hz, H-7), 7.84 (1H, d, Jo ¼ 8.4 Hz, H-4), 7.47
(1H, m, Jo ¼ 7.6 Hz, Jo ¼ 7.6 Hz, Jm ¼ 1.1 Hz, H-6), 7.36 (1H, m,
Jo ¼ 7.3 Hz, Jo ¼ 7.3 Hz, Jm ¼ 1.1 Hz, H-5), 4.32 (2H, q, H-30), 1.32
(3H, t, H-40) ppm; 13C NMR (100 MHz, DMSO-d6) d: 159.1 (C-20),
157.9 (C-10), 157.4 (C-2), 147.5 (C-3a), 131.4 (C-7a), 126.5 (C-6),
124.2 (C-5), 122.0 (C-7), 120.5 (C-4), 62.7 (CH2), 13.7 (CH3) ppm;Please cite this article in press as: G. Navarrete-Vazquez, et al., Synthes
thiazol-2-ylamino)-2-oxoacetates as protein-tyrosine phosphatase 1B inh
j.ejmech.2012.04.025MS/FABþ: m/z 251 (M þ Hþ). HRMS (FABþ): m/z 251.0483
[M þ H]þ (Calculated for C11H10N2O3SHþ 251.0490).
4.1.1.3. Ethyl 2-(6-methoxybenzo[d]thiazol-2-ylamino)-2-oxoacetate
(OX-3). Yield: 45%, mp: 182e184 C. 1H NMR (400 MHz, DMSO-
d6) d: 7.69 (1H, d, Jo ¼ 8.8 Hz, H-4), 7.61 (1H, d, Jm ¼ 2.4 Hz, H-7),
7.06 (1H, dd, Jm ¼ 2.4 Hz, Jm ¼ 2.4 Hz, Jo ¼ 8.8 Hz, H-5), 4.31 (2H,
q, CH2), 3.80 (3H, s, CH3O), 1.31 (3H, t, CH3) ppm; 13C NMR
(100 MHz, DMSO-d6) d: 159.0 (C-20), 156.8 (C-10), 156.4 (C-2),
155.4 (C-6), 141.8 (C-3a), 132.8 (C-7a) 121.2 (C-5), 115.3 (C-7),
104.7 (C-4), 62.6 (CH2), 55.6 (CH3O) 13.7 (CH3) ppm; MS/FABþ: m/
z 281 (M þ Hþ). HRMS (FABþ): m/z 281.0587 [M þ H]þ
(Calculated for C12H12N2O4SHþ 281.0596).
4.1.1.4. Ethyl 2-(6-ethoxybenzo[d]thiazol-2-ylamino)-2-oxoacetate
(OX-4). Yield: 44%, mp: 176e178 C. 1H NMR (400 MHz, DMSO-
d6) d: 7.68 (1H, d, Jo ¼ 8.8 Hz, H-4), 7.59 (1H, d, Jm ¼ 2.2 Hz, H-7),
7.05 (1H, dd, Jm ¼ 2.2 Hz, Jm ¼ 2, Jo ¼ 8.8 Hz, H-5), 4.31 (2H, q,
CH2), 4.06 (2H, q, CH2), 1.34 (3H, t, CH3), 1.31 (3H, t, CH3) ppm.;
13C NMR (100 MHz, DMSO-d6) d: 168.4 (C-20), 159.0 (C-10), 156.8
(C-2), 155.6 (C-6), 141.7 (C-3a), 132.8 (C-7a) 121.2 (C-5), 115.6 (C-
7), 105.3 (C-4), 63.6 (CH2), 62.6 (CH2), 14.7 (CH3) 13.7 (CH3) ppm;
MS/FABþ: m/z 295 (M þ Hþ). HRMS (FABþ): m/z 295.0770
[M þ H]þ (Calculated for C13H14N2O4SHþ 295.0753).
4.1.1.5. Ethyl 2-{6-(methylsulfonyl)benzo[d]thiazol-2-ylamino}-2-
oxoacetate (OX-5). Yield: 98%, mp: 209e212 C. 1H NMR
(400 MHz, DMSO-d6) d: 8.14 (1H, s, H-7), 7.77 (1H, d, Jo ¼ 8 Hz,
H-4), 7.46 (1H, dd, Jo ¼ 8 Hz, Jm ¼ 1 Hz, H-5), 4.3 (2H, q, CH2),
2.49 (3H, s, CH3), 1.31 (3H, t, CH3) ppm; 13C NMR (100 MHz,
DMSO-d6) d: 162.7 (C-20), 159.7 (C-10), 158.6 (C-2), 152.6 (C-3a),
137.2 (C-6), 133.2 (C-7a), 126.2 (C-7) 123.5 (C-4), 122.2 (C-5), 64.1
(CH2), 45.1 (CH3), 15.0 (CH3) ppm; MS/FABþ: m/z 329 (M þ Hþ).
HRMS (FABþ): m/z 329.0233 [M þ H]þ (Calculated for
C12H12N2O5S2Hþ 329.0266).
4.1.1.6. Ethyl 2-(6-chlorobenzo[d]thiazol-2-ylamino)-2-oxoacetate
(OX-6). Yield: 47%, mp: 218e221 C. 1H NMR (400 MHz, DMSO-
d6) d: 8.13 (1H, s, H-7), 7.76 (1H, d, Jo ¼ 8.4 Hz, H-4), 7.48 (1H, dd,
Jm ¼ 1.2 Hz, Jo ¼ 8.4 Hz, H-5), 4.30 (2H, q, CH2), 1.30 (3H, t, CH3)
ppm; 13C NMR (100 MHz, DMSO-d6) d: 159.9 (C-20), 159.5 (C-10),
158.2 (C-2), 148.0 (C-3a), 134.3 (C-7a), 129.4 (C-5) 127.9 (C-6),
122.9 (C-4), 122.6 (C-7), 64.0 (CH2), 15.08 (CH3) ppm; MS/FABþ:
m/z 285 (M þ Hþ). HRMS (FABþ): m/z 285.0091 [M þ H]þ
(Calculated for C11H9ClN2O3SHþ 285.0101).
4.1.1.7. Ethyl 2-(6-fluorobenzo[d]thiazol-2-ylamino)-2-oxoacetate
(OX-7). Yield: 63%, mp: 214e215 C. 1H NMR (400 MHz, DMSO-
d6) d: 7.93 (1H, dd, Jm, HeH ¼ 2.6 Hz, Jo, HeF ¼ 8.72 Hz, H-7), 7.81
(1H, dd, Jo, HeH ¼ 8.92 Hz, Jm, HeF ¼ 4.8 Hz, H-4), 7.32 (1H, td, Jm,
HeH ¼ 2.7 Hz, Jo, HeH ¼ 9.12 Hz, Jo, HeF ¼ 9.04 Hz, H-5), 4.32 (2H,
q, CH2), 1.31 (3H, t, CH3) ppm; 13C NMR (100 MHz, DMSO-d6) d:
158.9 (d, J ¼ 239.24 Hz, C-6), 158.93 (C-20), 157.5 (C-10), 157.1 (d,
Jp ¼ 0.81 Hz, C-3a), 144.8 (C-2), 132.8 (d, Jm ¼ 11.39 Hz, C-7a),
122.0 (d, Jm ¼ 9.05 Hz, C-4), 114.6 (d, Jo ¼ 24.57 Hz, C-7), 108.3 (d,
Jo ¼ 26.69 Hz, C-5), 62.7 (CH2), 13.7 (CH3) ppm; MS/FABþ: m/z
269 (M þ Hþ). HRMS (FABþ): m/z 269.0392 [M þ H]þ (Calculated
for C11H9FN2O3SHþ 269.0396).
4.1.1.8. Ethyl 2-(6-nitrobenzo[d]thiazol-2-ylamino)-2-oxoacetate
(OX-8). Yield: 80%, mp: 255 C (dec). 1H NMR (400 MHz, DMSO-
d6) d: 9.03 (1H, s, H-7), 8.24 (1H, dd, Jo ¼ 8.8 Hz, Jm ¼ 1 Hz, H-5),
7.89 (1H, d, Jo ¼ 8.8 Hz, H-4), 4.30 (2H, t, CH2) 1.31 (3H, t, CH3)
ppm; 1C NMR (100 MHz, DMSO-d6) d: 162.8 (C-20), 158.3 (C-10),
157.2 (C-2), 152.6 (C-3a), 143.2 (C-6), 132.1 (C-7a) 121.7 (C-4),is, in vitro and in silico screening of ethyl 2-(6-substituted benzo[d]
ibitors, European Journal of Medicinal Chemistry (2012), doi:10.1016/
G. Navarrete-Vazquez et al. / European Journal of Medicinal Chemistry xxx (2012) 1e10 9120.8 (C-7), 119.1 (C-5), 62.9 (CH2), 13.7 (CH3) ppm; MS/FABþ: m/z
296 (M þ Hþ). HRMS (FABþ): m/z 296.0393 [M þ H]þ (Calculated
for C11H9N3O5SHþ 296.0341).
4.1.1.9. Ethyl 2-(6-aminobenzo[d]thiazol-2-ylamino)-2-oxoacetate
(OX-9). Yield: 90%, mp: 290 C (dec). 1H NMR (400 MHz, DMSO-
d6) d: 6.84 (1H, s, H-7), 6.60 (1H, dd, Jo ¼ 8.8 Hz, Jm ¼ 1 Hz, H-5),
7.59 (1H, d, Jo ¼ 8.8 Hz, H-4), 4.32 (2H, t, CH2) 1.34 (3H, t, CH3)
ppm; 13C NMR (100 MHz, DMSO-d6) d: 158.2 (C-20), 156.5 (C-10),
150.4 (C-2), 148.4 (C-3a), 145.7 (C-6), 127.1 (C-7a) 122.1 (C-4),
113.8 (C-5), 103.8 (C-7), 63.2 (CH2), 14.7 (CH3) ppm; MS/FABþ: m/z
266 (M þ Hþ). HRMS (FABþ): m/z 266.0578 [M þ H]þ (Calculated
for C11H11N3O3SHþ 266.0593).
4.2. Biological assays
4.2.1. PTP-1B expression and purification
All experiments were conducted using human recombinant
PTP-1B. Briefly, the complete sequence of PTP-1B was cloned in the
pGEX-2T bacterial expression vector downstream the GST
sequence. This vector was used to transform E. coli TB1 strain cells.
The recombinant fusion protein was purified from bacterial lysate
using a single-step affinity chromatography. The solution contain-
ing purified fusion protein was treated with thrombin for 3 h at
37 C. Then the PTP-1B was purified from GST and thrombin by gel
filtration on a Superdex G75 column. The purity of PTP-1B prepa-
ration was assessed by SDSepolyacrylamide gel electrophoresis.
4.2.2. Enzyme assays [10]
All assays were carried out at 37 C. The substrate (p-nitro-
phenylphosphate) was dissolved in 0.075 M of b,b-dimethylgluta-
rate buffer pH 7.0, containing 1 mM EDTA and 1 mM dithiothreitol.
The final volume was 1 mL. The reactions were initiated by adding
aliquots of the enzyme (0.16 mg for each test), and stopped at
appropriate times with 4 mL of 1 M KOH. The released p-nitro-
phenol was determined by reading the absorbance at 400 nm
( 3¼ 18,000 M1 cm1). The main kinetic parameters (Km and Vmax)
were determined by measuring the initial rates using eight
different substrate concentrations in the 0.5e40 mM range.
Experimental data were analyzed using the MichaeliseMenten
equation and a nonlinear fitting program (FigSys).
To evaluate the inhibition power of compounds OX-1, OX-6, and
OX-7 we calculated the IC50 value using a fixed substrate concen-
tration corresponding to the Km of enzyme and varying inhibitor
concentrations. The IC50 value was calculated by fitting experi-
mental data with a non-nonlinear fitting program (FigSys, Biosoft,
UK), using the equation:
y ¼ MaxMin
1þ

x
IC50
slope þMin
where “y” is vi/vo, i.e. the ratio between the activity measure in the
presence of the inhibitor (vi) and the activity of the control without
the inhibitor (vo). The parameter “x” is the inhibitor concentration.
4.2.3. Animals
MaleWistar rats weighing 200e250 g bodyweight were housed
at standard laboratory conditions and fed with a rodent pellet diet
and water ad libitum. They were maintained at room temperature
and at a photoperiod of 12 h day/night cycle. Animals described as
fasted were deprived of food for 18 h but had free access to water.
All animal procedures were conducted in accordance with our
Federal Regulations for Animal Experimentation and Care
(SAGARPA, NOM-062-ZOO-1999, México), and approved by thePlease cite this article in press as: G. Navarrete-Vazquez, et al., Synthes
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Institute of Health publication (No. 85-23, revised 1985).
4.2.4. In vivo hypoglycemic assay
Animals were divided into groups of five animals each (n ¼ 5).
Experimental groups were orally treated with a single dose
(100 mg/kg body weight) of suspension of the compounds OX-1,
OX-6, and OX-7 (prepared in 5% Tween 80). Control group
animals were also fed with 5% Tween 80. Glibenclamide (10 mg/kg)
was used as hypoglycemic reference drug. Blood samples were
collected from the caudal vein at 0, 1, 3, 5, and 7 h after vehicle,
sample and drug administration. Blood glucose concentration was
estimated by enzymatic glucose oxidase method using a commer-
cial glucometer (Accutrend GCT, Roche). The percentage variation
of glycemia for each group was calculated in relation to initial (0 h)
level, according to: %Variation of glycemia ¼ [(Gx  G0)/G0]  100,
where G0 were initial glycemia values and Gx were the glycemia
values at þ1, þ3, þ5 and þ7 h, respectively. All values were
expressed as mean  S.E.M. Statistical significance was estimated
by analysis of variance (ANOVA), p < 0.05 implies significance.
4.2.5. Oral glucose tolerance test [11]
After a food overnight deprivation of 18 h, normoglycemic rats
(n ¼ 5) were subjected to an oral glucose tolerance test (OGTT) to
investigate the short-term hypoglycemic effect of the compounds.
Compounds OX-1 and OX-6 (100 mg/kg), vehicle, acarbose
(10 mg/kg), repaglinide (4 mg/kg) and glibenclamide (5 and
10 mg/kg) were administered to rats in the equal volume of
suspension, and 10 min after received a single dose of glucose (2 g/
kg) by de same route. Blood samples were collected from the tail tip
at 0 (before oral administration), 0.5, 1, 2, 3 and 4 h after vehicle,
positive controls and samples administration. Blood glucose
concentration was estimated as described.
4.2.6. Docking
Molecular Operating Environment (MOE) 2009.10 was used for
ligand and protein preparation, and molecular structure viewing.
The crystal structure was obtained from the PDB with the accession
code 1C83 [8]. Docking calculations were conducted with Auto-
Dock, version 4.0 [12]. In short, AutoDock performs an automated
docking of the ligand with user-specified dihedral flexibility within
a protein rigid binding site. The program performs several runs in
each docking experiment. Each run provides one predicted binding
mode. All water molecules and 6-(oxalyl-amino)-1H-indole-5-
carboxilic acid (crystallographic ligand) were removed from the
crystallographic structure and all hydrogen atoms were added. For
all ligands and protein, Gasteiger charges were assigned and
nonpolar hydrogen atoms were merged. All torsions were allowed
to rotate during docking. The auxiliary program AutoGrid gener-
ated the grid maps. Each grid was centered at the crystallographic
coordinates of the crystallographic compound. The grid dimensions
were 22.12  22.12  22.12 A3 with points separated by 0.375 A.
LennardeJones parameters 12e10 and 12e6, supplied with the
program, were used for modeling H-bonds and Van der Waals
interactions, respectively. The Lamarckian genetic algorithm was
applied for the search using default parameters. The number of
docking runs was 100. After docking, the 100 solutions were clus-
tered into groups with RMS lower than 1.0 A. The clusters were
ranked by the lowest energy representative of each cluster. In order
to describe the ligand-binding pocket interactions, the top ranked
binding mode found by AutoDock in complex with the binding
pocket of PTP-1B was subject to full energy minimization using the
MMFF94 force field implemented in MOE until the gradient 0.05
was reached. PyMOL 1.0 [13] was used to generate the molecular
surface of docking models.is, in vitro and in silico screening of ethyl 2-(6-substituted benzo[d]
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